Sexual health

The Site-Specific STI Picture for Men Who Have Sex With Men

Save

A single urine sample answers only part of the question for anyone having oral or anal sex, since gonorrhea and chlamydia don't confine themselves to the urethra. This piece lays out which sites actually need checking, how often, what HIV prevention options exist alongside routine testing, and where doxy-PEP fits for people with a recent bacterial STI — the site-specific picture that a routine panel alone can miss.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why does screening for MSM look different from a standard STI test?

A standard urine test only checks the urethra, but gonorrhea and chlamydia can also infect the rectum and throat, sites a urine sample never reaches 1. For anyone having anal or oral sex, testing only the urethra can miss an infection entirely, even when it's the only site involved.

That gap matters because sti symptoms in men, when they appear at all, tend to track the site of infection — throat and rectal infections often cause no symptoms a person would notice, which is part of why relying on symptoms to decide what to test is unreliable at any site. How each of these swabs is actually collected, and what a full panel includes, is covered in more depth in a guide on asking for the full panel at a clinic visit.

How often should testing happen, and for what?

National guidance recommends that sexually active MSM be tested at least annually for syphilis, chlamydia, and gonorrhea, at whichever sites reflect actual sexual activity, along with HIV testing that CDC recommends at least once for everyone regardless of perceived risk 2 3.

People with multiple or anonymous partners, or those on PrEP, are often tested more frequently — every three to six months rather than annually — since more partners means more opportunities for exposure between visits. The mechanics of that testing, including what naat testing actually detects at each site, are covered separately; what matters here is which sites and infections the schedule is built around.

Why the throat and rectum specifically matter

Gonorrhea and chlamydia are both capable of infecting the throat after oral sex and the rectum after anal sex, in addition to the urethra, and each site is tested separately since infection at one site doesn't reliably show up in a test of another 1. Someone can test negative at the urethra and still be carrying gonorrhea in the throat or rectum.

This is part of a much broader pattern: the asymptomatic sti majority holds across all three sites, not just the genital one, so a person who feels completely fine can still be infected and still be capable of passing an infection to a partner. Regular, scheduled testing, rather than symptom-triggered testing, is what actually catches infections at sites that rarely announce themselves.

What about syphilis, herpes, and HPV?

Syphilis screening is part of the same annual recommendation covering chlamydia and gonorrhea for sexually active MSM, and like those two, an early syphilis infection can be entirely painless and easy to miss 3. A blood test, not a swab, is what catches it, which is one more reason a single visit built around genital swabs alone leaves gaps.

Herpes and HPV work differently and aren't part of the same routine bacterial-and-HIV panel. Herpes testing generally depends on a visible sore rather than a routine blood draw, and there's no HPV test currently approved for men in the U.S., so both infections tend to come up through symptom evaluation or, for HPV, through the cancers it's occasionally linked to over time, rather than through scheduled screening the way chlamydia, gonorrhea, syphilis, and HIV do.

What to actually tell a clinician to get the right tests

Testing the right sites and infections depends heavily on the clinician knowing what kind of sex is actually happening, since a routine panel doesn't automatically include throat or rectal swabs, or syphilis and HIV testing, unless it's specifically requested or built into that clinic's standard protocol for MSM patients 2 3. Being specific about anal sex, oral sex, number of recent partners, and whether protection was used is what actually shapes which tests get ordered.

That conversation can feel exposing, but it's a routine part of sexual health care rather than an unusual request, and clinics that regularly see MSM patients are generally comfortable having it directly. Bringing it up explicitly, instead of hoping it gets inferred from context, is usually what closes the gap between a standard visit and one that actually covers the relevant sites and infections.

HIV prevention: PrEP, and what to do after a specific exposure

PrEP, taken consistently, reduces the risk of getting HIV from sex by about 99%, and is available as a daily pill or a longer-acting injectable option — but it does not protect against chlamydia, gonorrhea, syphilis, or any other STI, which is why it works alongside testing rather than replacing it 4. Someone starting PrEP still needs the same site-specific screening schedule as someone who isn't on it.

For a specific recent exposure rather than ongoing risk, PEP is the separate option: starting antiretroviral medication ideally within 24 hours and no later than 72 hours after a possible exposure, taken for a 28-day course, with follow-up testing at 4 to 6 and 12 weeks 5. The 72-hour decision guide covers exactly what that window involves and how to move quickly when it applies. Someone who ends up starting PEP repeatedly, for recurring exposures rather than a single incident, is often a reasonable candidate to talk with a clinician about switching to ongoing PrEP instead.

Doxy-PEP: an additional layer for some

For MSM and transgender women who've had a bacterial STI — syphilis, chlamydia, or gonorrhea — in the past year, current guidance supports offering doxy-PEP: a dose of the antibiotic doxycycline taken after sex to lower the chance of a future bacterial STI 6.

Doxy-PEP isn't recommended universally — it's targeted at people with a recent bacterial STI, reflecting a higher near-term chance of another one, and anyone using it is also advised to keep testing every three to six months rather than treating the medication itself as a reason to test less 6. It doesn't touch HIV, viral infections like herpes or HPV, or trichomoniasis, so it supplements the rest of this picture rather than simplifying it.

Common questions

Yes, if oral or anal sex is part of your sexual activity. Gonorrhea and chlamydia can infect the throat and rectum as well as the urethra, and an infection at one site doesn't reliably show up on a test of another, so each exposed site needs its own swab.

At least annually for syphilis, chlamydia, and gonorrhea is the general baseline, with HIV testing recommended at least once for everyone. People with multiple or anonymous partners, or those on PrEP, are often tested more frequently, roughly every three to six months.

No. PrEP is highly effective at preventing HIV specifically but provides no protection against chlamydia, gonorrhea, syphilis, or other STIs. Routine testing for those infections continues on its own schedule regardless of PrEP use.

PrEP is taken on an ongoing basis before any exposure to prevent HIV from ever taking hold. PEP is a short emergency course started within 72 hours after a specific possible exposure and taken for 28 days — it's for a one-time situation, not ongoing prevention.

Current guidance supports offering it to MSM and transgender women who've had a bacterial STI in the past year. It's not recommended as a routine option for everyone, and it doesn't protect against HIV or viral infections.

Testing the right sites depends on the clinician knowing what kind of sex you're having, since a standard visit doesn't automatically include throat or rectal swabs. Being specific about oral and anal sex, rather than assuming it will come up, is usually what gets the right sites tested.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When to seek care sooner than a routine test

  • —A possible HIV exposure within the last 72 hours
  • —Rectal pain, bleeding, or discharge
  • —A new sore, ulcer, or rash, especially with fever or swollen lymph nodes
  • —Sore throat with white patches or difficulty swallowing after oral sex

A possible HIV exposure within the last 72 hours needs same-day evaluation — an urgent care clinic, ER, or sexual health clinic can start PEP; waiting past 72 hours may mean it's no longer an option.

This explains the general site-specific screening picture for MSM; it is educational information, not individualized medical advice. Testing frequency and site selection should be discussed directly with a clinician based on actual sexual activity.

References

  1. 1.Centers for Disease Control and Prevention (2024). About Gonorrhea. CDC (cdc.gov/gonorrhea). linkSupports that gonorrhea is a bacterial STI that can infect the genitals, rectum, and throat, and is often asymptomatic.
  2. 2.Centers for Disease Control and Prevention (2024). Getting Tested for STIs. CDC (cdc.gov/sti). linkSupports that MSM are recommended to be tested at least annually for syphilis, chlamydia, and gonorrhea, that everyone 13-64 should be tested at least once for HIV, and that self-collection options exist.
  3. 3.Centers for Disease Control and Prevention (2021). STI Screening Recommendations. CDC STI Treatment Guidelines, 2021. linkSupports CDC's population-specific STI screening recommendations, including screening intervals for MSM.
  4. 4.Centers for Disease Control and Prevention (2024). Clinical Guidance for PrEP. CDC HIV Nexus. linkSupports that PrEP, taken as prescribed, reduces the risk of getting HIV from sex by about 99%, that oral and injectable (cabotegravir) PrEP options exist, and that PrEP does not protect against other STIs.
  5. 5.Centers for Disease Control and Prevention (2025). Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025. MMWR Recommendations and Reports, Vol. 74, No. 1. doi:10.15585/mmwr.rr7401a1Supports the current CDC guidelines for nonoccupational HIV PEP: first dose ideally within 24 hours and no later than 72 hours after exposure, a 28-day course, and follow-up testing at 4-6 and 12 weeks.
  6. 6.Bachmann LH, Barbee LA, Chan P, et al. (Centers for Disease Control and Prevention) (2024). CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024. MMWR Recommendations and Reports, Vol. 73, No. 2. doi:10.15585/mmwr.rr7302a1 ✓Supports the 2024 CDC doxy-PEP guideline: recommends counseling and offering doxycycline taken after sex to MSM and transgender women who had a bacterial STI in the prior 12 months, with STI testing every 3-6 months.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library